Cellectar Biosciences, Inc.

CLRB

$2.35

-3.29%

N/A-$0.08

Healthcare

Biotechnology

NASDAQ

Active Trading

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's ...

Fundamental Analysis of CLRB

Key Strengths

Platform-driven precision oncology approach using proprietary PDC technology, aiming for selective tumor targeting

Multiple clinical programs for CLR 131 across hematologic malignancies and other trial settings, providing several potential value-inflection points

Risk Factors

High probability of continued losses and negative operating cash flow typical of development-stage biotech, increasing financing/dilution risk

Clinical and regulatory risk: trial outcomes may be unfavorable, endpoints may not be met, or safety/tolerability could limit adoption

Profitability

Net Margin0.00%

Operating Margin0.00%

Valuation

P/E Ratio-0.52x

Current Ratio6.66

Efficiency

ROE-165.71%

ROA-60.93%

Fundamental Analysis of CLRB

Cellectar Biosciences, Inc. (CLRB) is a clinical-stage biotechnology company developing phospholipid drug conjugates (PDCs) designed to deliver chemotherapy more selectively to tumors. The company’s lead asset, CLR 131 (iopofosine I-131), is in Phase 2 studies across multiple indications, including relapsed/refractory (r/r) Waldenström’s macroglobulinemia and B-cell malignancies, Phase 2B in r/r multiple myeloma, and Phase 1 programs in several pediatric and other solid-tumor contexts. A secondary PDC program (CLR 1900) remains preclinical, and the platform approach is supported by collaborations to advance additional PDC series with partners. Fundamentally, CLRB is best characterized as a high-risk, pre-revenue-to-early-development model. The provided trailing-twelve-month (TTM) market data shows a market cap of ~$20.7M with a very limited liquidity profile relative to average daily volume (volume far below average), which can amplify volatility. Profitability metrics are not meaningful in the dataset: margins (gross/operating/net/EBITDA) are effectively shown as 0, net income per share is negative, and return measures (ROE/ROA) are deeply negative—consistent with a company that has not yet reached sustainable operating earnings. Balance sheet support appears strong on liquidity ratios: current ratio (6.66) and quick ratio (6.66) suggest substantial current assets relative to current liabilities, and debt appears low (debt-to-equity ~0.051). However, leverage coverage metrics such as interest coverage are effectively unavailable/0 due to weak earnings power. Free cash flow yield and operating cash flow metrics are negative (FCF and operating cash flow are materially worse than zero), indicating continued cash burn typical for development-stage biopharma. Given this profile, valuation multiples like P/E are not reliable (negative earnings), while price-to-book (~1.06) may offer limited comfort because biotech assets are largely R&D-driven and often not reflected fully in book value. Analyst sentiment for small-cap, clinical-stage oncology developers is generally highly dependent on clinical readouts and financing outcomes; without up-to-date financial statements (income/CF/BS history beyond ratios) and the absence of current consensus inputs here, risk remains elevated. Overall, CLRB’s core investment case hinges on clinical progression of CLR 131 and the translation of the PDC platform into registrational or meaningfully commercializable outcomes. For long-term investors, the decision is primarily about probability-weighted pipeline success versus dilution/financing needs.

Key Strengths of CLRB

Platform-driven precision oncology approach using proprietary PDC technology, aiming for selective tumor targeting
Multiple clinical programs for CLR 131 across hematologic malignancies and other trial settings, providing several potential value-inflection points
Demonstrated collaborative capability to expand PDC series development with established partners
Strong reported liquidity positioning (high current and quick ratios), reducing immediate near-term solvency pressure
Low stated leverage (low debt-to-equity and debt-to-assets), which can mitigate financial risk during burn
High potential upside if Phase 2/2B results translate into improved response rates, durability, or regulatory pathways

Risk Factors of CLRB

High probability of continued losses and negative operating cash flow typical of development-stage biotech, increasing financing/dilution risk
Clinical and regulatory risk: trial outcomes may be unfavorable, endpoints may not be met, or safety/tolerability could limit adoption
Small market cap and thin trading relative to average volume can increase volatility and investor accessibility risk
Valuation metrics are difficult to interpret due to negative earnings (P/E negative and margins effectively not meaningful), limiting standard fundamental valuation frameworks
Financing/strategic-alternative risk: need for additional capital could force equity issuance on unfavorable terms
Industry and macro risk: capital market tightening and biotech risk-off cycles can materially impact funding availability and share price
Concentration risk: primary dependence on CLR 131’s progress; slower or failed outcomes in lead programs can dominate overall company valuation

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$18.86M

-0.5x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin0.00%

Net Profit Margin0.00%

Debt/Equity Ratio0.05

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of CLRB

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of CLRB

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	0.00%	—	—	Flat
Operating Margin	—	0.00%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of CLRB

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	6.659	—	—	Flat
Quick Ratio	—	6.659	—	—	Flat
Debt / Equity	—	0.051	—	—	Flat

Valuation of CLRB

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-1.22x	—	—	Flat
P/B	—	1.14x	—	—	Flat

Supply Chain of CLRB

RELATIONS

Upstream

SpectronRxLantheus Holdings (via Evergreen Theragnostics acquisition)NASDAQ:LNTHNorthStar Medical RadioisotopesITM Isotope Technologies Munich SENusanoIonetix CorporationUnconfirmed

Downstream

MiBA (Meaningful Insights-BioTech Analytics) / American Oncology NetworkOTCPK:AONCEvestia ClinicalMayo Clinic

Proxies

Actinium Pharmaceuticals, Inc.NYSEAM:ATNMPerspective Therapeutics, Inc.NYSE:CATX Lantheus Holdings, Inc.NASDAQ:LNTH

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer